Immunogenicity and safety of live attenuated hepatitis A vaccine: A multicentric study

Indian Pediatrics

Volumn 46, Issue 1, 2009, Pages 29-34

  Faridi, M M A ^a   Shah, Nitin ^b   Ghosh, T K ^c   Sankaranarayanan, V S ^d   Arankalle, Vidya ^e   Aggarwal, Anju ^a   Sathiyasekaran, Malathi ^d   Bhattacharya, Nisha ^c   Vasanthi, T ^d   Chatterjee, Suparna ^f   Choudhury, Jaydeep ^c   Mitra, Monjori ^g  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

^b Lion Tarachand Bapa Hospital   (India)

^c INSTITUTE OF CHILD HEALTH   (India)

^d KANCHI KAMAKOTI CHILDS TRUST HOSPITAL   (India)

^e NATIONAL INSTITUTE OF VIROLOGY   (India)

^f INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^g Medclin Research   (India)

Author keywords

Hepatitis A vaccine; Immunogenicity; Live attenuated; Safety; Single dose

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; LIVE VACCINE;

ABSENCE OF SIDE EFFECTS; AGED; ANTIBODY TITER; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HEPATITIS A; HUMAN; IMMUNOGENICITY; INDIA; INFANT; MAJOR CLINICAL STUDY; PRESCHOOL CHILD;

CHILD, PRESCHOOL; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; IMMUNOASSAY; INFANT; MALE;

EID: 58849112568     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Jindal M, Rana SS, Gupta RK, Das K, Kar P. Serological study of hepatitis A virus infection amongst the students of a medical college in Delhi and evaluation of the need of vaccination. Indian J Med Res 2002; 115: 1-4.
2. Joshi N, Yr NK, Kumar A. Age related seroprevalence of antibodies to hepatitis A virus in Hyderabad, India. Trop Gastroenterol 2000; 1: 63-65.
3. Arankalle VA, Tsarev SA, Chadha MS, Alling DW, Emerson SU, Banerjee K, et al. Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992. J Infect Dis 1995; 171: 447-450.
4. Arankalle VA, Chadha MS, Chitambar SD, Walimbe AM, Chobe LP, Gandhe SS. Changing epidemiology of hepatitis A and hepatitis E in urban and rural India (1982-1998). J Viral Hepat 2001; 8: 293-303.
5. Indian Academy of Pediatrics Committee on Immunization. Hepatitis A vaccine. In: Shah RC, Shah NK, Kukreja S, eds. Guidebook on Immunization. Mumbai: Indian Academy of Pediatrics 2006: 32-33,79.
6. WHO. Hepatitis A vaccines, Position paper. Wkly Epidemiol Rec 2000; 75:38-42.
7. Bhave S, Bavdekar A, Madan Z, Jha R, Bhure S, Chaudhari J, et al. Evaluation of immunogenicity and tolerability of a live attenuated hepatitis a vaccine in Indian children. Indian Pediatr 2006; 43: 983-987.
8. Lemon SM. Type A viral hepatitis: Epidemiology, diagnosis and prevention. Clin Chem 1997; 43:1494-1499.
9. Ambrosch F, Widermann G, Andre FE. Comparison of HAV antibodies induced by vaccination, passive immunization and natural infection. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Other Liver Disease. Baltimore: Williams and Wilkins; 1991. p. 98-100.
10. Berger R, Just M, Beat A. Time course of hepatitis A/antibody production after active, passive and active/passive immunization: the results are highly dependent on the antibody test system used. J Vir Meth 1999; 13: 287-298.
11. Nolan T, Bernstein H, Blatter MM., Bromberg K, Gueria F, Kennedy W, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age. Pediatrics 2006;118: e602-609.
12. Wang XY, Xu ZY, Ma JC, Von Seidlein L, Zhang Y, Hao ZY, et al. Long-term immunogenecity after single and booster dose of a live attenuated hepatitis A: Results from 8-year follow-up. Vaccine 2007; 25 : 446-449.
13. Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS 2005; 19: 1702-1704.
14. Zhuang F, Qian W, Mao ZA, Gong YP, Jiang Q, Jiang LM, et al. Persistent efficacy of live attenuated hepatitis A vaccine (H2 strain) after a mass vaccination program. Chin Med J 2005; 118: 1851-1856.
15. Xu Z, Wang X, Li R, Meng Z, Zhang Y,Gong J, et al. Immunogenecity and efficacy of two live attenuated hepatitis vaccines (H2 strain and LA-1strains) Zhonghua Yi Xue Za Zhi 2002; 82: 678-681.
16. Mao JS, Chai SA, Xic RY, Chen NL, Jiang Q, Zhu XZ, et al. Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans. Vaccine 1997; 15: 944-947.